**Preface**

**Biotarget: a platform to rapidly disseminate knowledge and exchange experiences in biotarget molecules**

It is my pleasure and great privilege to present the starting issue of *Biotarget* to you. This is a new international peer-reviewed journal devoted to the rapid publication of high-quality studies related to identifying key biotarget molecules and the application of biotarget molecules in human and animal disease, available in print and online. The principal aim of *Biotarget* is to provide an insight for researchers to develop molecular tools and to identify molecular targets for the diagnosis and treatment of a variety of diseases (including cancer, diabetes, neurodegeneration, heart disease, inflammation, immune disease and metabolic disease etc.). Meanwhile, *Biotarget* is also to provide a free platform for rapid dissemination of latest original research articles as well as cutting-edge review articles in all areas related to biotarget molecules in medicine and life science.

Nowadays, more and more biological molecules are applied in medicine and life science. *Biotarget* strives to report the most recent advances in biotarget molecules research in wide field. *Biotarget* will feature: (I) original articles: reporting on novel and original findings about biotarget molecules and molecular biology; (II) review articles: both solicited and unsolicited review articles about biotarget molecules in specific field are welcome; (III) systematic review and meta-analysis; (IV) short communication; (V) perspective; (VI) correspondence; (VII) editorial; (VIII) commentary; (IX) viewpoint; (X) case report; (XI) meeting report; (XII) technical notes; (XIII) brief reports and (XIV) clinical guidelines.

All articles can be submitted electronically online. The entire submission and review process will be managed through editorial manager. Here, I am sure that the online system of AME Publishing Company of *Biotarget* manuscript submission and review will be straight forward and user-friendly. Our goal is to provide a prompt and efficient platform for scientific publications with outstanding editorial support. Every effort we made contributes to presenting readers of *Biotarget* with a new, well-constructed, informative, and educational journal.

I am honored to serve as the Editor-in-Chief of *Biotarget*, and very grateful to have a team of excellent scientists and physicians join the editorial board. We promise to work together diligently, and I am confident that *Biotarget* will continue to publish high quality papers rapidly and take the lead in the field of biotarget molecules.

At this historical moment for *Biotarget*, we would like to thank all our colleagues for their assistance and endeavor to make the launch of this newborn journal possible. Of course, your future support and nurture on *Biotarget* would be greatly appreciated. We are also grateful to our editorial board members and staff for their diligence in copy editing, paper processing and journal promotion.

Maorong Jiang

*Laboratory Animal Center, Nantong University, Nantong 226001, China. *(Email: Jiangmr@ntu.edu.cn)

doi: 10.21037/biotarget.2017.02.01

Conflicts of Interest: The author has no conflicts of interest to declare.

View this article at: http://dx.doi.org/10.21037/biotarget.2017.02.01

do: 10.21037/biotarget.2017.02.01

Cite this article as: Jiang M. Biotarget: a platform to rapidly disseminate knowledge and exchange experiences in biotarget molecules. Biotarget 2017;1:1.